Opus Genetics, INC. (IRD) — SEC Filings

Overview

Opus Genetics, INC. (IRD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 144 filed on Apr 23, 2026: Benjamin R. Yerxa, reporting for Opus Genetics, Inc., filed a Form 144 on April 23, 2026, indicating a proposed sale of securities. The filing provides mailing and business addresses for both Inspire Pharmaceuticals, Inc. and Opus Genetics, Inc., with Opus Genetics being a Delaware-incorporated comp

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 1 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Opus Genetics, INC. is neutral.

Filing Type Overview

Opus Genetics, INC. (IRD) has filed 2 144, 28 8-K, 1 EFFECT, 5 10-Q, 4 DEFA14A, 2 10-K, 1 8-K/A, 1 SC 13D, 1 DEF 14A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• 8-K Filing — 8-K · Apr 24, 2026
• 144 Filing — 144 · Apr 23, 2026
• Opus Genetics Files Form 144 for Proposed Securities Sale — 144 · Apr 23, 2026 Risk: medium
  Benjamin R. Yerxa, reporting for Opus Genetics, Inc., filed a Form 144 on April 23, 2026, indicating a proposed sale of securities. The filing provides mailing
• EFFECT Filing — EFFECT · Apr 23, 2026
• 8-K Filing — 8-K · Apr 22, 2026
• 8-K Filing — 8-K · Apr 7, 2026
• Opus Genetics Relocates Principal Executive Offices — 8-K · Dec 19, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K on December 19, 2025, reporting an event on December 17, 2025. The filing indicates a change in the company's principal executi
• Opus Genetics' Loss Widens Amid Gene Therapy Push, Warrant Costs — 10-Q · Nov 12, 2025 Risk: high
  Opus Genetics, Inc. (IRD) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $33.068 million, up from $22.397 mi
• Opus Genetics Files 8-K — 8-K · Nov 6, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K on November 6, 2025, reporting on other events and financial statements. The company, formerly known as Ocuphire Pharma, Inc.,
• Opus Genetics Files 8-K with Regulatory Updates — 8-K · Sep 30, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K on September 30, 2025, reporting on events that occurred on the same date. The filing includes information related to Regulatio
• Opus Genetics Files 8-K on Officer/Director Changes — 8-K · Sep 2, 2025 Risk: medium
  Opus Genetics, Inc. filed an 8-K on August 29, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain
• Opus Genetics Reports Unregistered Equity Sales — 8-K · Aug 25, 2025 Risk: medium
  Opus Genetics, Inc. filed an 8-K on August 25, 2025, reporting unregistered sales of equity securities. The filing does not specify the number of shares sold or
• Opus Genetics Narrows Q2 Loss, Boosted by Viatris Revenue — 10-Q · Aug 13, 2025 Risk: medium
  Opus Genetics, Inc. (IRD) reported a net loss of $7.42 million for the three months ended June 30, 2025, a slight improvement from the $7.765 million net loss i
• Opus Genetics Enters Material Definitive Agreement — 8-K · Jul 23, 2025 Risk: medium
  On July 22, 2025, Opus Genetics, Inc. entered into a material definitive agreement. The filing also includes information regarding Regulation FD disclosure and
• Opus Genetics Files 8-K — 8-K · Jun 26, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K on June 26, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific detail
• Opus Genetics Files 8-K on Leadership and Compensation Changes — 8-K · Jun 25, 2025 Risk: medium
  On June 25, 2025, Opus Genetics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indica
• Opus Genetics Files 8-K: Reg FD & Financials — 8-K · Jun 23, 2025 Risk: low
  On June 23, 2025, Opus Genetics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. The co
• Opus Genetics Enters Material Definitive Agreement — 8-K · Jun 20, 2025 Risk: medium
  On June 13, 2025, Opus Genetics, Inc. entered into a material definitive agreement. The company, formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceutic
• Opus Genetics Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Opus Genetics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Ocuphire Pharma, Inc., is in the pharmaceuti
• Opus Genetics Files 8-K on Shareholder Vote Matters — 8-K · May 1, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K on May 1, 2025, reporting on matters submitted to a vote of security holders as of April 30, 2025. The filing does not contain
• Opus Genetics Files Definitive Proxy Materials — DEFA14A · Apr 14, 2025 Risk: low
  Opus Genetics, Inc. filed a Definitive Additional Materials proxy statement on April 14, 2025. This filing relates to the company's solicitation of proxies for
• Opus Genetics Files Proxy Materials — DEFA14A · Apr 11, 2025 Risk: low
  Opus Genetics, Inc. filed a Definitive Additional Materials proxy statement on April 11, 2025. This filing relates to the company's solicitation of proxies for
• Opus Genetics Files Proxy Materials — DEFA14A · Apr 10, 2025 Risk: low
  Opus Genetics, Inc. filed a Definitive Additional Materials proxy statement on April 10, 2025. This filing is an amendment to previous proxy materials and does
• Opus Genetics Files Proxy Materials — DEFA14A · Apr 7, 2025 Risk: low
  Opus Genetics, Inc. filed a Definitive Additional Material proxy statement on April 7, 2025. This filing relates to the company's proxy materials and does not i
• Opus Genetics Terminates Material Definitive Agreement — 8-K · Apr 4, 2025 Risk: medium
  Opus Genetics, Inc. announced on April 2, 2025, the termination of a material definitive agreement. The company, formerly known as Ocuphire Pharma, Inc., filed
• Opus Genetics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Opus Genetics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Ocuphire Pharma
• Opus Genetics Files 8-K on Equity Sales — 8-K · Mar 24, 2025 Risk: medium
  Opus Genetics, Inc. filed an 8-K on March 24, 2025, reporting unregistered sales of equity securities and other events. The filing also includes financial state
• Opus Genetics Files 8-K on Operations — 8-K · Mar 20, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing indicates the company's principal
• Opus Genetics Files 8-K for Bylaw Amendments & Financials — 8-K · Mar 20, 2025 Risk: low
  On March 19, 2025, Opus Genetics, Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws, other events, a
• Opus Genetics Files 8-K for Other Events — 8-K · Mar 4, 2025 Risk: medium
  Opus Genetics, Inc. filed an 8-K on March 4, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, doll
• Opus Genetics Announces Board and Executive Changes — 8-K · Jan 24, 2025 Risk: medium
  Opus Genetics, Inc. announced on January 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure of cer
• Opus Genetics (fka Ocuphire Pharma) Files 8-K — 8-K · Jan 23, 2025 Risk: low
  On January 23, 2025, Opus Genetics, Inc. filed an 8-K report. The filing indicates that the company's former name was Ocuphire Pharma, Inc., with a name change
• Opus Genetics Files 8-K — 8-K · Jan 14, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K on January 14, 2025, reporting "Other Events" and "Financial Statements and Exhibits" as of January 13, 2025. The company, form
• Opus Genetics Files 8-K/A Amendment — 8-K/A · Jan 7, 2025 Risk: low
  Opus Genetics, Inc. filed an 8-K/A on January 7, 2025, to amend a previous filing regarding financial statements and exhibits. The original event date reported
• Opus Genetics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Opus Genetics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Ocuphire Pharma, Inc., reported financial results an
• Foundation Fighting Blindness Files 13D on Opus Genetics — SC 13D · Oct 29, 2024 Risk: medium
  Foundation Fighting Blindness, Inc. filed a Schedule 13D on October 29, 2024, regarding their ownership of Opus Genetics, Inc. The filing indicates a change in
• Ocuphire Pharma Acquired by Lumina Acquisition Corp. — 8-K · Oct 22, 2024 Risk: medium
  Ocuphire Pharma, Inc. announced on October 22, 2024, the completion of its acquisition by Lumina Acquisition Corp. The transaction, which was previously announc
• Ocuphire Pharma Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: medium
  Ocuphire Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operat
• Ocuphire Pharma Files 8-K with Corporate Updates — 8-K · Jun 13, 2024 Risk: low
  Ocuphire Pharma, Inc. filed an 8-K on June 13, 2024, reporting events that occurred on June 11, 2024. The filing indicates changes related to the company's arti
• Ocuphire Pharma Files 8-K on Operations and Financials — 8-K · May 10, 2024 Risk: low
  Ocuphire Pharma, Inc. filed an 8-K on May 10, 2024, reporting on its results of operations and financial condition. The filing also includes financial statement
• Ocuphire Pharma Schedules 2024 Annual Meeting of Stockholders for June 11 — DEF 14A · Apr 29, 2024 Risk: low
  Ocuphire Pharma, Inc. (IRD) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Ocuphire Pharma, Inc. will hold its 2024 Annual Meeting of Stockho
• Ocuphire Pharma Appoints New Director — 8-K · Apr 17, 2024 Risk: low
  Ocuphire Pharma, Inc. announced on April 11, 2024, a change in its board of directors. Specifically, Dr. Robert L. Van Sickle has been appointed to the Board of
• Ocuphire Pharma Files 8-K for Disclosure and Exhibits — 8-K · Mar 27, 2024 Risk: low
  Ocuphire Pharma, Inc. filed an 8-K on March 27, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• Ocuphire Pharma Files 2023 Annual Report on Form 10-K — 10-K · Mar 8, 2024 Risk: medium
  Ocuphire Pharma, Inc. (IRD) filed a Annual Report (10-K) with the SEC on March 8, 2024. Ocuphire Pharma, Inc. filed its annual report on Form 10-K for the fisca
• Ocuphire Pharma Reports Officer Compensation Changes — 8-K · Feb 16, 2024 Risk: medium
  Ocuphire Pharma, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 12, 2024. The filing pertains to changes in compensatory a

Risk Profile

Risk Assessment: Of IRD's 40 recent filings, 1 were flagged as high-risk, 19 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Opus Genetics, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $10.331M
• Net Income: -$33.068M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $30.815M
• Operating Margin: N/A
• Total Assets: $36.122M
• Total Debt: $30.155M

Key Executives

• Benjamin R. Yerxa
• Dr. Robert L. Van Sickle

Industry Context

The gene therapy sector for inherited retinal diseases (IRDs) is a rapidly evolving and highly competitive field. Companies in this space are characterized by significant R&D investment, reliance on complex intellectual property, and the need for substantial capital to navigate lengthy clinical trials and regulatory approvals. Key trends include advancements in gene editing technologies, the pursuit of treatments for rare genetic disorders, and strategic partnerships or acquisitions to expand pipeline diversity.

Top Tags

corporate-governance (8) · filing (5) · financials (4) · corporate-actions (4) · 8-k (3) · financial-reporting (3) · exhibits (3) · 10-Q (3) · pharmaceuticals (3) · amendment (3)

Key Numbers

• Net Loss: $33.068M — Increased from $22.397 million for the nine months ended September 30, 2024
• License and Collaborations Revenue: $10.331M — Increased from $6.690 million for the nine months ended September 30, 2024
• Warrant Liabilities: $21.325M — Increased from $0 at December 31, 2024, reflecting new financings
• Cash and Cash Equivalents: $30.815M — As of September 30, 2025, expected to fund operations for at least 12 months
• Accumulated Deficit: $172.066M — Increased from $138.998 million at December 31, 2024
• Common Stock Shares Outstanding: 64,544,096 — As of September 30, 2025, up from 31,574,657 at December 31, 2024
• Fair Value Change in Warrant and Other Derivative Liabilities: $5.803M — Non-cash expense for the nine months ended September 30, 2025
• General and Administrative Expenses: $17.093M — Increased from $10.918 million for the nine months ended September 30, 2024
• SEC File Number: 001-34079 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 11-3516358 — Company's tax identification number.
• Net Loss (Q2 2025): $7.42M — Slight improvement from $7.765M in Q2 2024
• Net Loss (6 months ended June 30, 2025): $15.614M — Increased from $14.871M in 2024
• License and Collaborations Revenue (6 months ended June 30, 2025): $7.252M — Significant increase from $2.823M in 2024
• Total Operating Expenses (6 months ended June 30, 2025): $26.087M — Increased from $18.859M in 2024
• Cash and Cash Equivalents (June 30, 2025): $32.429M — Increased from $30.321M at Dec 31, 2024

Related Companies

VTRS · OPUS · OCUP

Frequently Asked Questions